Clinical trials of HSP90 inhibitors in combination with doxorubicin (terminated) [99] or carboplatin and paclitaxel (ORR = 0%) [100] have not demonstrated efficacy in SCLC, though other combinations, such as with BCL2 inhibition, may be more effective. The gene discussed is BCL2; the disease is small cell lung carcinoma.